The "Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2024" clinical trials has been added tAndMarkets.com's offering.The clinical trial report provides an overview of Sicca Syndrome (Sjogren ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2024" clinical trials has been added to ...

Primary Sjogren syndrome is a systemic autoimmune disorder most commonly presenting with sicca symptoms. It is far from a rare disorder, with an incidence approaching approximately one-half of that of ...

HYDERABAD: We’ve all heard people shouting “Ho, Ho, Ha, Ha, Ha” in parks, and when we follow the sounds, we often discover it ...

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, and Laboratoires Théa (Théa), the leading independent ...

AAV-AQP1 is under clinical development by MeiraGTx and currently in Phase II for Sicca Syndrome (Sjogren). According to GlobalData, Phase II drugs for Sicca Syndrome (Sjogren) does not have sufficient ...

We observed no sicca, telangiectasias, calcinosis ... We ruled out a diagnosis of antiphospholipid syndrome because the results of the 3 antiphospholipid antibody tests were normal. The absence of ...

The Sicca Syndrome (Sjogren) drugs in development market research report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis ...

France Sjögren Syndrome (SS) classically associates sicca syndrome, pain and asthenia. Systemic manifestations may develop with potentially severe organ damage including pulmonary, neurological, renal ...

To assess the risk of lymphoproliferative disease or other malignancy (standardised incidence ratios (SIRs)), in patients with primary Sjögren’s syndrome according to the American-European Consensus ...